Locations:
Search IconSearch
October 8, 2021/Cancer

Stereotactic Radiosurgery for Brain Metastases (Podcast)

Why it remains the mainstay for newly diagnosed metastases and tumors

Cleveland Clinic Cancer Advances · Stereotactic Radiosurgery in the Treatment Landscape for Brain Metastases

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Brain metastases are about 10 times more common than primary brain tumors in adults, so it is really important that medical oncologists and primary care doctors are tuned into the possibility of their patients with cancer developing brain metastases,” says neurosurgeon Gene Barnett, MD, MBA, Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “The treatment options are better if we get to these metastases when they are smaller and/or asymptomatic.”

One treatment option is stereotactic radiosurgery, a minimally invasive intervention that uses targeted radiation beams to treat brain tumors and other abnormalities. In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Barnett discusses the evolution of traditional surgical approaches for treating patients with brain metastases and the ability of stereotactic radiosurgery to deliver superior outcomes. He provides insight on the following:

  • Presenting symptoms of brain metastases
  • The range of treatment options, from surgical interventions to medication and radiation therapies
  • A step-by-step look at the stereotactic radiosurgery procedure
  • The emergence and promising results of neoadjuvant stereotactic surgery
  • The importance of combining systemic therapies with radiosurgery for tumor control

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt.

Excerpt from the podcast

Podcast host Dale Shepard, MD, PhD: What does [stereotactic radiosurgery] look like from a patient perspective, in terms of what their experience is as they undergo the treatment and how well they’re likely to do? When I see patients in clinic and I tell them they have a lung met or a liver met, they’re not nearly as frightened as when I tell them they have a brain met. So how do we reassure patients?

Advertisement

Dr. Barnett: Well, I think that’s totally understandable because people understand the brain is who we are and allows us to do what we want to do. Many people know, or know of, people who have had brain tumors and have not done well. I think the point of reassurance is that we can actually do a really good job of controlling brain metastases these days with radiosurgery, to the extent that most people who have brain metastases don’t die from them — rather, they die of their systemic disease and their brain disease is under control. For the vast majority of brain metastases, the control rate is upwards of 90% to 95%. And with the staged technique, the control is typically durable. So, I think that giving patients the facts should be consoling. You don’t want to sugarcoat things, but the facts are that the outcome is actually probably a lot better than what they were thinking.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad